An Update on the Ongoing Federal Response to COVID-19: Current Status and Future Planning
June 16, 2022
- Testimony of
Robert M. Califf, M.D., MACC
Commissioner of Food and Drugs - Food and Drug Administration
Chair Murray, Ranking Member Burr, distinguished members of the Committee, thank you for the opportunity to testify before you today to describe the Food and Drug Administration’s (FDA’s or the Agency’s) coronavirus disease 2019 (COVID-19) response efforts. All of our efforts are in close coordination and collaboration with our partners, both within the Department of Health and Human Services (HHS) and across the federal government, to help ensure the development, authorization, licensure, approval, and availability of critical, safe, and effective medical products to address the COVID-19 public health emergency.